Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Limited has updated its disclosure authorization following the resignation of its Company Secretary and Compliance Officer, Mr. Vinay Kumar Mishra, effective June 10, 2026. The company has authorized its Managing Director, Mr. Swapnil Jatinbhai Shah, and Whole Time Director & CFO, Mr. Deval Rajnikant Shah, to determine the materiality of events and make disclosures to the stock exchanges as per SEBI (LODR) Regulations, 2015. This update follows their earlier intimation on May 14, 2026, regarding Mr. Mishra's resignation.

Senores Pharmaceuticals Ltd. reported no deviations or variations in the utilization of funds raised through the preferential issue of 11,70,000 convertible equity warrants for the quarter ended March 31, 2026. The funds, amounting to ₹95,00,40,000, were raised on March 28, 2026. The Audit Committee reviewed the statement, and the Board of Directors took it on record on May 14, 2026. The original allocation included funding working capital (₹31,25,30,000), product development (₹25,00,00,000), subsidiary investment (₹15,00,00,000), and general corporate purposes (₹23,75,10,000).

Senores Pharmaceuticals Ltd. reported a correction to its previously released media statement regarding the audited financial results for the quarter and fiscal year ending March 31, 2026. The corrected release highlights strong financial performance, with total income for FY26 reaching ₹664 Cr, a 62% increase year-over-year. EBITDA grew by 96% to ₹200 Cr, and PAT increased by 108% to ₹122 Cr. The company also noted significant growth in regulated markets, emerging markets, and branded generics businesses, along with strategic acquisitions and joint ventures to expand its market presence.

Senores Pharmaceuticals Ltd reported no deviation or variation in the utilization of funds raised through its IPO for the quarter ended March 31, 2026. The IPO raised ₹500 Crores. While some delays occurred in deploying funds for the Havix subsidiary due to geopolitical issues, the company received management approval to utilize the funds by Fiscal 2027. The audit committee and board of directors reviewed and approved the statement on May 14, 2026.

Senores Pharmaceuticals Ltd. has released the Monitoring Agency Report for the quarter ended March 31, 2026, as per SEBI regulations. The report, issued by CARE Ratings Limited, concerns the utilization of IPO proceeds. The Audit Committee and Board of Directors reviewed and recorded the report on May 14, 2026. The report indicates a delay in implementing one of the objects which was scheduled to get completed by FY26.

Senores Pharmaceuticals Ltd announced its audited consolidated and standalone financial results for FY26. The company reported a 65% increase in total income to ₹664 Cr and a 114% increase in EBITDA to ₹200 Cr. PAT increased by 108% to ₹122 Cr. The company highlighted strong growth in regulated markets, emerging markets, and branded generics businesses, along with strategic acquisitions and a joint venture in the U.S. Federal Market.

Senores Pharmaceuticals Ltd. has released its audited financial results for the quarter and financial year ended March 31, 2026. The board approved the consolidated and standalone financial results with an unmodified opinion from the statutory auditors, M/s. Pankaj R. Shah and Associates. Additionally, the company announced the resignation of Company Secretary and Compliance Officer, Mr. Vinay Kumar Mishra, effective June 10, 2026, and the appointment of Sharp & Tannan Associates as the Internal Auditor for FY 2026-27.

Senores Pharmaceuticals Ltd. announced the approval of audited consolidated and standalone financial results for the quarter and financial year ended March 31, 2026, with an unmodified opinion from auditors M/s. Pankaj R. Shah and Associates. The company also announced the resignation of Company Secretary and Compliance Officer Mr. Vinay Kumar Mishra, effective June 10, 2026, and the appointment of Sharp & Tannan Associates as the Internal Auditor for FY 2026-27.

Senores Pharmaceuticals Ltd has scheduled a Board of Directors meeting on May 14, 2026, to consider and approve the audited consolidated and standalone financial results for the quarter and financial year ended March 31, 2026. The trading window for dealing in the company's securities has been closed since April 1, 2026, and will remain closed until 48 hours after the results are approved and submitted to stock exchanges.

Senores Pharmaceuticals Limited has announced a strategic joint venture through its US subsidiary, Senores Pharmaceuticals, Inc. The joint venture, named Amerisyn, LLC, will enable Senores to supply its high-quality product portfolio to the U.S. Federal Government, veterans affairs and military supply contracts. This partnership is expected to be a significant driver of growth and a substantial contributor to Senores' international business volumes.